BP Dataset | TC Dataset | |
---|---|---|
n(%) or mean ± SD | n(%) or mean ± SD | |
Number of patients | 991 | 956 |
Female | 879 (88.7%) | 849 (88.8%) |
Race | ||
Caucasian | 70% | 70% |
Black | 11% | 11% |
Asian | 11% | 11% |
Other | 8% | 8% |
CAD events | ||
MI Angina | 25 75 | 20 71 |
Sudden cardiac death | 2 | 2 |
Total | 94 | 86 |
Agea | ||
At diagnosis | 31.0 ± 13.8 | 30.9 ± 13.8 |
At study entry | 37.1 ± 14.0 | 37.5 ± 14.1 |
Disease durationa | ||
At first clinic visit | 4.0 ± 5.8 | 4.0 ± 5.9 |
At study entry | 6.1 ± 7.9 | 6.6 ± 8.1 |
SLEDAI-2Kb | ||
At first clinic visit | 9.7 ± 7.7 | 9.6 ± 7.7 |
At study entry | 9.2 ± 7.5 | 8.3 ± 7.2 |
SLICC/ACR-DIc | ||
At first clinic visit | 0.3 ± 0.7 | 0.3 ± 0.7 |
At study entry | 0.5 ± 1.2 | 0.6 ± 1.2 |
Steroids at study entry | 623 (63%) | 625 (65.6%) |
Antimalarials at study entryd | 380 (38.5%) | 385 (40.4%) |
Immunosuppressivese | ||
At study entry | 235 (23.8%) | 233 (24.5%) |
Hypertension at study entryf | 221 (22.3%) | 212 (22.6%) |
Hypercholesterolemia at study entryg | 344 (41.8%) | 408 (42.7%) |
Diabetes at study entryh | 28 (2.9%) | 31 (3.3%) |
Smoker at study entryi | 190 (19.5%) | 183 (19.5%) |
Antihypertensive use | ||
at study entryj | 174/691 (25.2%) | 174/699 (24.9%) |
Lipid-lowering meds | ||
at study entryk | 23/440 (5.2%) | 22/440 (5.0%) |